GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.

Bharat Biotech and GSK plc will significantly reduce the price of their malaria vaccine, Mosquirix, to under $5 per dose by 2028. This price cut, exceeding 50%, is part of their commitment to Gavi ...

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners, by ...

Bharat Biotech International and GSK plc in their commitment to Gavi, the Vaccine Alliance will be reducing the price of RTS.S, developed by GSK, PATH and partners, by more than half, to less than $5 ...

LONDON, June 25 (Reuters) - Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they said on Wednesday.

The announcement was made by Bharat Biotech and GSK as a part of Gavi, the Vaccine Alliance, for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies.

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech Published: June 12, 2025, 4:48 a.m. ET Share Resize ...